Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluticasone/Salmeterol vs Advair Diskus in Healthy Volunteers
NCT03751202Phase 1Completed
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Nov 2018
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate and salmeterol in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Respirent Pharmaceuticals Co. Ltd. Primary endpoints: Area under the plasma concentration curve from time 0 to the last measured and Maximum plasma concentration. Started Nov 2018; status: completed.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03751202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03751202.